Pulmonx Corporation (NASDAQ:LUNG) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET

Company Participants

Laine Morgan - Gilmartin Group

Glen French - President and Chief Executive Officer

Derrick Sung - Chief Financial Officer

Conference Call Participants

Cecilia Furlong - Morgan Stanley

Travis Steed - BofA Securities

David Ko - Canaccord Genuity

Larry Biegelsen - Wells Fargo

Joseph Downing - PSC

Joanne Wuensch - Citi

Operator

Good afternoon, and welcome to Pulmonx Second Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Laine Morgan from the Gilmartin Group for a few introductory comments.

Laine Morgan

Good afternoon, and thank you for participating in today's call. Joining me from Pulmonx are Glen French, President and Chief Executive Officer; and Derrick Sung, Chief Financial Officer. Earlier today, Pulmonx released financial results for the quarter ended June 30, 2022. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind you that Management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor position of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call that relate to the expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, the impact of COVID-19 on our business and prospects for recovery, expense management, expectations for hiring, growth and organization, market opportunities, guidance for revenue, gross margin and operating expenses, commercial expansion and product pipeline development are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the Securities and Exchange Commission, including the quarterly report on Form 10-Q filed with the SEC on May 9, 2022.

This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 2, 2022. The Pulmonx Corporation disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. And with that, I will turn the call over to Glen.